The following content is sponsored by Americans for a limited government:
The Trump administration should aim for intermediaries that increase healthcare costs.
In his quest to eliminate wasted federal spending, President Trump has a factory-sized cheesecake menu of choice when it comes to healthcare. When the Trump administration draws attention to the sector, it quickly turns out that foreign aid is merely an appetizer to the fat centers of bloated health devices in America.
The government's health program, Medicaid, is intended to provide compensation to Americans with low incomes and disabilities. In 2023 alone, the Non-Participant Accountability Office discovered that the program lost $50 billion in “inappropriate payments” used to explain waste and fraud. It's more than a USAID thing Total budget For the year.
Last year, the Federal Trade Commission said that the Pharmacy Benefits Manager (PBMS) “abused economic strength by favourably digging into competition in the drug supply chain, and forced patients to pay more for life-saving drugs. The total revenue for PBMS is over $1 trillion, equivalent to 22% of the national health spending. This reveals American healthcare that is very different from other healthcare, and the answer is that American healthcare is plagued by a maze of intermediary insurance brokers driven by benefits rather than patient care.
In today's world, providers and patients no longer have control over healthcare and need to constantly navigate the rise in Red tapes resulting from Middleman Meddling in the healthcare supply chain. Middlemen continues to claim that it is cutting healthcare costs in the United States. So, you'd think Americans would get something for all this spending, but patients' costs are actually skyrocketing.
The Biden administration exacerbated the problem by increasing the bureaucracy of the health system through laws such as the Inflation Reduction Act (IRA). The IRA hit Medicare with an adjustment of about $273 billion, with some of the savings being poured into massive insurance bailouts to hide the high costs of Obamacare plans.
However, these intermediaries reduce the efficiency of the system. recently study We found that increased third-party healthcare costs lead to increased spending and waste. Without controlling the dollar, patients lose the ability to make their choices and shop for better prices.
Who thrives with inefficiency, you might ask? Intermediate. Prescription drugs are a great case study. Believing that the high costs of certain drugs were due to lack of government involvement, Biden's IRA was in charge of “negotiating” the drug prices with federal officials. However, the law was willing to ignore much bigger issues. The presence of a pharmacy benefit manager (PBM) negotiates a rebate with a drug manufacturer and quietly pockets most of the savings intended to go to patients.
2024 US Federal Trade Commission Report “These powerful intermediaries may be profiting by inflating drug costs and narrowing down pharmacies on Main Street.” The report states that three largest PBMs are now “as a result,” nearly 80% of all prescriptions filled in the US. [PBMs] The enormous power and influence on patients' access to drugs and the prices they pay. ”
The 340B drug pricing program is another inefficiency that empowers intermediaries over patients. Under 340B, hospitals can purchase discounted medications for uninsured and low-income patients. However, the 340B has become a hospital markup program. Many 340B hospitals and PBMs they use to buy drugs have found a way to gaming the system. One of the biggest PBMSs, CVS, revealed it would incorporate Large profit From 340b.
The former CEO of the corporate chain pharmacy company said the scale of the 340B program has exploded and “make the most of it.” “We expect the overall 340b revenue to increase from $116 billion in 2021 to $28 billion in 2026. We intend to make the most of the momentum this sector presents.”
Instead of handing out the discounted price to vulnerable patients, the 340B hospital charges the patient or insurance company for the full price of the drug, pocketing the differences and sharing revenue with the PBM.
The madness of intermediaries within the American health care system must cease. President Trump has the opportunity to expose how much PBM and 340B abuse drive US health costs. Congress should pass much-needed reforms that will curb this waste and protect patients.
The Trump administration should also find ways to reduce administrative spending on healthcare. FDA-led Trump candidate Dr. Marty McCurry famously It is called attention The administration must blow whi away with red tape that drives waste to hospitals, leaving hospitals throwing away clean, disposable medical devices. All dollars spent on administrative overhead are dollars that are not invested in patient care or next-generation healthcare innovation.
The Trump administration can help patients by distracting resources from programs that don't make America healthy. Now is the time.
